HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Oral tolvaptan is safe and effective in chronic hyponatremia.

Abstract
Vasopressin antagonists increase the serum sodium concentration in patients who have euvolemia and hypervolemia with hyponatremia in the short term (</=30 days), but their safety and efficacy with longer term administration is unknown. SALTWATER was a multicenter, open-label extension of the Study of Ascending Levels of Tolvaptan in Hyponatremia (SALT-1 and SALT-2). In total, 111 patients with hyponatremia received oral tolvaptan for a mean follow-up of 701 days, providing 77,369 patient-days of exposure. All patients had hyponatremia at randomization in SALT-1 and SALT-2, and 85% continued to have hyponatremia at entry in SALTWATER. The most common adverse effects attributed to tolvaptan were pollakiuria, thirst, fatigue, dry mouth, polydipsia, and polyuria. Six drug-related adverse effects led to study discontinuation. The increase in serum sodium exceeded the desired 1 mmol/L per h at initiation in five patients. Hypernatremia (>145 mmol/L) led to discontinuation in one patient. Mean serum sodium increased from 130.8 mmol/L at baseline to >135 mmol/L throughout the observation period (P < 0.001 versus baseline at most points). Responses were comparable between patients with euvolemia and those with heart failure but more modest in patients with cirrhosis. In conclusion, prolonged administration of tolvaptan maintains an increased serum sodium with an acceptable margin of safety.
AuthorsTomas Berl, Friederike Quittnat-Pelletier, Joseph G Verbalis, Robert W Schrier, Daniel G Bichet, John Ouyang, Frank S Czerwiec, SALTWATER Investigators
JournalJournal of the American Society of Nephrology : JASN (J Am Soc Nephrol) Vol. 21 Issue 4 Pg. 705-12 (Apr 2010) ISSN: 1533-3450 [Electronic] United States
PMID20185637 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Antidiuretic Hormone Receptor Antagonists
  • Benzazepines
  • Tolvaptan
Topics
  • Administration, Oral
  • Antidiuretic Hormone Receptor Antagonists
  • Benzazepines (administration & dosage)
  • Chronic Disease
  • Female
  • Humans
  • Hyponatremia (drug therapy)
  • Male
  • Middle Aged
  • Tolvaptan

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: